Saifu Pharmaceutical

Saifu Pharmaceutical was established in 2016, relying on national-level drug research and development institutions such as the Innovation Academy for Drug Research of the Chinese Academy of Sciences, with the aim of creating a world-class one-stop innovative drug CRO service platform. The company owns the following facilities: the Gu'an Drug Safety Evaluation Center, the Beijing Pharmacology and Efficacy Center, the Shenzhen Non-clinical Evaluation Center for New Drugs, the Chengdu Model Animal Center, the Beijing Pharmaceutical and Clinical Research Center, the Shenyang Bioanalysis Center, and the U.S.-based Saifu office responsible for FDA registration submissions. Additionally, it has self-built GCP clinical trial bases at four Class-III Grade-A hospitals.Saifu Pharmaceutical's one-stop service integrates different stages of drug R&D, effectively improving R&D efficiency, reducing costs, and shortening the R&D cycle. It has multiple technical departments including drugability evaluation, model animals, pharmacology and efficacy, preclinical safety evaluation, pharmacokinetic analysis, R&D consulting and registration submission, Phase I clinical trials and bioanalysis, pharmaceutical formulation, RCT clinical trials, and pharmacovigilance, providing comprehensive innovative drug R&D solutions. The company currently has over 400 scientific researchers, nearly 60 of whom hold doctorates. The core R&D team is composed of former experts from the Chinese Academy of Sciences, the Academy of Military Medical Sciences, and domestic and international review specialists. A scientific committee led by academicians has been established, including international experts in pathology diagnosis, toxicology, NMPA and FDA regulatory submission, and GLP inspection, covering the entire innovative drug R&D and evaluation industry chain. The technical team has led several major national new drug creation projects, including the National 863 Program, the 973 Program, and key projects of the Natural Science Foundation, with experience in the non-clinical and clinical evaluation of more than 600 drugs and over 2,000 non-clinical and clinical trial projects. The company has received investments from professional investment institutions such as Legend Capital, China Life Healthcare, and SDIC Venture Capital, and has been recognized as a National High-tech Enterprise, a Beijing-based technology SME, and a Zhongguancun High-tech Enterprise.